ChemicalBook > CAS DataBase List > Flotetuzumab

Flotetuzumab

Product Name
Flotetuzumab
CAS No.
1664355-28-5
Chemical Name
Flotetuzumab
Synonyms
Flotetuzumab;Research Grade Flotetuzumab;Research Grade Flotetuzumab (DHD72504)
CBNumber
CB38081017
Formula Weight
0
MOL File
Mol file
More
Less

Flotetuzumab Property

form 
Liquid
color 
Colorless to light yellow
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

Flotetuzumab Chemical Properties,Usage,Production

Uses

Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML)[1][2].

in vivo

Flotetuzumab (0.5-4 μg/kg; intraperitoneal implantation; continuous infusion for 6 d) shows antitumor activity in human peripheral blood mononuclear cells (PBMCs)-reconstituted tumor-bearing mice[1].
Flotetuzumab (0.5 mg/kg; once every 5 d; for 30 d) improves mouse survival and induces T-cell proliferation in mouse NTPL-146 patient-derived xenograft (PDX) model of acute myeloid leukemia (AML)[2].

Animal Model:PBMCs-reconstituted tumor model: NSG/β2m-/- mice intradermally implanted with the KG-1a (AML-M0) cells on day 0 and intraperitoneally injected with human PBMCs on day 1[1]
Dosage:0.5 μg/kg, 1 μg/kg, and 4 μg/kg;
Administration:Peritoneally implantation with mini-osmotic pumps; continuous infusion from days 16 to 22;
Result:Inhibited tumor volume significantly.

References

[1] Chichili GR, et al. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates. Sci Transl Med. 2015 May 27;7(289):289ra82. DOI:10.1126/scitranslmed.aaa5693
[2] Barwe SP, et al. Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia. J Clin Med. 2022 Feb 28;11(5):1333. DOI:10.3390/jcm11051333

Flotetuzumab Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Flotetuzumab Suppliers

ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Fax
QQ:2853530913
Email
2853530910@QQ.com
Country
China
ProdList
8000
Advantage
62
Wuhan Chemstan Biotechnology Co., Ltd.
Tel
027-65317797 15926423062
Fax
QQ:422450190
Email
422450190@qq.com
Country
China
ProdList
10308
Advantage
58
Biolab Reagents
Tel
027-65279366 18108604356
Email
products@biolabreagent.com
Country
China
ProdList
9868
Advantage
58
Wuhan Jingkangen Biomedical Technology Co., Ltd
Tel
13720134139 086-15871494362 13720134139
Email
orders@jknbiochem.com
Country
China
ProdList
6762
Advantage
58
Shanghai Yifei Biotechnology Co. , Ltd.
Tel
021-65675885 18964387627
Email
customer_service@efebio.com
Country
China
ProdList
11973
Advantage
58
Changsha Fuzhen Biotechnology Co.,LTD
Tel
0731-13823398 15111215862
Email
313359644@qq.com
Country
China
ProdList
4161
Advantage
58
Olix (Shanghai) Pharmaceutical Technology Co., Ltd
Tel
17316404525 17316404525
Email
209533805@qq.com
Country
China
ProdList
9763
Advantage
58
Atagenix Laboratories
Tel
027-87008169 17762441161
Email
info@atagenix.com
Country
China
ProdList
10001
Advantage
58
AntibodySystem Laboratories SAS
Tel
33175446423
Email
support@antibodysystem.com
Country
China
ProdList
6739
Advantage
58
Biosynth Biological Technology (Suzhou) Co Ltd
Tel
51288865780
Email
sales@biosynth.com
Country
China
ProdList
6051
Advantage
58

1664355-28-5, FlotetuzumabRelated Search:


  • Flotetuzumab
  • Research Grade Flotetuzumab (DHD72504)
  • Research Grade Flotetuzumab
  • 1664355-28-5